marketshareAI
Theme

BSF Enterprise

BSFAHealthcare
2.2330GBX
-4.98%
Market Cap
2.76M
Volume
601.41k
46% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
3.2
Day Range
2.2330p - 2.5000p
52 Week Range
0.9200p2.2330p4.1950p
2.2330p

Upcoming Events

17 December 2025
General Meeting to approve the equity fundraise and capital reorganization
High Impact Event
Next 12 months
Joint development of cost-effective large-scale production of cells and tissues for 3DBT's lab-grown meat and leather products
High Impact Event
2026
Kerato to begin collecting animal data for groundbreaking liquid cornea trial
High Impact Event
30 January 2026
Expected completion of the equity fundraise
High Impact Event
Early 2027
First-in-human clinical study for LiQD Cornea
High Impact Event
2033
Global corneal transplant market expected to reach USD 1.86 billion
High Impact Event
BSFA
NEUTRAL

BSF Enterprise Launches New Investor Website

The biotechnology company has launched a new interactive investor website to improve communication with shareholders.

BSFA
NEUTRAL

BSF Enterprise Plc Announces £15 Million Equity Fundraise to Accelerate Commercialization

The biotechnology company plans a £15 million equity fundraise to support the commercialization of its lab-grown leather, corneal repair, and cell culture media technologies. The details of the raise are unclear, raising concerns about the terms and potential dilution for existing shareholders.

BSFA
BAD

BSF Enterprise Plc Announces £15 Million Equity Fundraise

The biotechnology company has announced a £15 million equity fundraise, with the shares being issued at a 23.8% discount to the previous closing price. The funds will be used to support the commercialization of the company's technologies.

BSFA
NEUTRAL

BSF Enterprise Chairman Resigns

The leading innovator in tissue-engineered materials has announced the resignation of its Chairman.

BSFA
GOOD

BSF Enterprise Signs Exclusive Worldwide Option Agreement for LiQD Cornea Technology

The biotechnology company has signed an exclusive worldwide option agreement for a novel corneal repair technology, positioning it to address a growing global burden of corneal blindness.

BSFA
BAD

BSF Enterprise Reports Interim Results: Revenue Down, Losses Narrow

The biotech firm reported a decrease in revenue and cash reserves, despite narrowing losses. It continues to develop innovative products but faces significant financial challenges.

BSFA
NEUTRAL

BSF Enterprise Amends Warrant Instrument

The biotechnology company has amended the terms of its outstanding warrants, reducing the exercise price and extending the expiration period.

BSFA
NEUTRAL

BSF Enterprise Provides Update on Lab-Grown Leather Progress

The biotechnology company provides an update on the progress of its lab-grown leather subsidiary, highlighting new product developments and partnerships.

BSFA
NEUTRAL

BSF Enterprise Announces Strategic Investment

The biotechnology company has conditionally placed new shares to bolster its strategic business and growth plans.

BSFA
NEUTRAL

BSF Enterprise PLC Announces Pioneering T-Rex Leather Joint Venture

The biotechnology company has partnered with a creative agency and a genomic engineering firm to produce sustainable luxury materials from prehistoric species, starting with T-Rex leather.